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Article

Cardiovascular Disease Risk Factors and Left
Ventricular Hypertrophy in Girls and Boys With CKD
Rebecca L. Ruebner,* Derek Ng,† Mark Mitsnefes,‡ Bethany J. Foster,§ Kevin Meyers, | Bradley Warady,¶ and
Susan L. Furth| **

Abstract
Background and objectives Prior studies suggested that women with CKD have higher risk for cardiovascular
disease (CVD) and mortality than men, although putative mechanisms for this higher risk have not been
identiﬁed. We assessed sex differences in (1) CVD risk factors and left ventricular hypertrophy (LVH), and (2) the
relationship of left ventricular mass (LVM) with different measures of body size in children with CKD.
Design, setting, participants, and measurements The study population comprised 681 children with CKD from
the Chronic Kidney Disease in Children cohort, contributing 1330 visits. CVD risk factors were compared crosssectionally by sex. LVH was deﬁned as LVM/height2.7 .95th percentile and LVM relative to estimated lean body
mass (eLBM) .95th percentile for age and sex. Differences in LVM by sex were assessed by adjusting for age,
weight, height, and eLBM using bivariate and multivariate regression models.
Results Girls were less likely to have uncontrolled hypertension (26% versus 38%, P=0.001), had lower diastolic
BP z-scores (+0.3 versus +0.6, P=0.001), and had lower prevalence of high triglycerides (38% versus 47%, P=0.03)
compared with boys. When LVH was deﬁned by LVM indexed to height, girls had higher prevalence of LVH
(16% versus 9%, P=0.01); when LVH was deﬁned by LVM relative to eLBM, prevalence of LVH was similar
between girls and boys (18% versus 17%, P=0.92). In regression models adjusting for eLBM, no sex differences in
LVM were observed.
Conclusions Despite lack of increased prevalence of CVD risk factors, indexing LVM to height showed a higher
proportion of LVH among girls, while estimates of LVH based on eLBM showed no sex differences. Indexing
LVM to eLBM may be an alternative to height indexing in children with CKD.
Clin J Am Soc Nephrol 11: 1962–1968, 2016. doi: 10.2215/CJN.01270216

Introduction
CKD increases the risk of cardiovascular disease
(CVD) in children and young adults, and cardiacrelated death is the leading cause of mortality in this
population (1,2). Young women with CKD have been
shown to be at even greater risk for mortality than
young men, although the reason for the higher risk of
death has not been determined (3,4).
A recently published report from the Chronic
Kidney Disease in Children (CKiD) study suggested
over four-fold higher odds of left ventricular hypertrophy (LVH) among girls compared with boys with
CKD, adjusted for known contributors to LVH, including hypertension and anemia (5). LVH is a signiﬁcant predictor of cardiovascular outcomes and is
associated with high rates of morbidity and mortality
in adults with CKD (6–8). Previous studies in adults
have shown higher risk of LVH among women compared with men at the same level of hypertension,
suggesting possible sex differences in the pathogenesis of LVH (9,10). However, sex-speciﬁc risk factors
for LVH have not previously been studied in the pediatric CKD population.
1962
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In addition, there is no agreed best method of
deﬁning LVH in children. Different methods of indexing left ventricular mass (LVM) for body size result in
signiﬁcantly different estimates of LVH prevalence (11).
While height and weight are related to LVM and sex,
lean body mass (LBM) may better account for sex and
age differences in LVM (12). However, transformations
of height and weight are often used to approximate
LBM. Recently published equations for estimated lean
body mass (eLBM) may be used to account for sex differences in LVM (13), but it is not known whether these
equations apply to children with CKD, who tend to
have lower height and higher weight for their age
and sex (14). Since LVM is directly related to LBM independent of sex (12), we sought to explore this relationship in children with CKD.
In order to evaluate the association of LVH with sex
among children with CKD, we sought to (1) compare
CVD risk factors by sex to investigate whether comorbidities not previously examined may explain
the higher LVH prevalence among girls, and (2) compare sex differences in LVM normalized relative to
different measures of body size.
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Materials and Methods
Study Population and Design
The CKiD study is an observational cohort study of
CKD in children being conducted at 46 centers in
North America (study website available at http://
www.statepi.jhsph.edu/ckid). Inclusion criteria include age 1–16 years and eGFR of 30–90 ml/min
per 1.73 m2 , calculated using the bedside CKiD study
formula (15). The full details of the CKiD study protocol, including exclusion criteria, have been described
previously (16). The CKiD study protocol has been reviewed and approved by the institutional review
boards of each participating center, and the study protocol adhered to the Declaration of Helsinki. All participants and/or guardians provided written informed
consent.
Clinical Variables
Casual BP was measured at study entry, then at annual
intervals after enrollment (17). Casual BPs were classiﬁed according to the National High Blood Pressure
Education Program Fourth Report on the Diagnosis,
Evaluation, and Treatment of High BP in Children and Adolescents (18): normotensive (,90th percentile), prehypertensive ($90th and ,95th percentiles),
and hypertensive ($95th percentile). Ambulatory BP
was measured as previously described (19). Elevated systolic and diastolic BP was based on mean
wake or sleep states greater than the expected 95th
percentile (20) or 25% of readings within each state
greater than the same threshold. Abnormally high
ambulatory BP was deﬁned as elevated systolic or
diastolic BP.
Weight, height, GFR, and blood and urine samples
were obtained on the day of the echocardiographic
evaluation. GFR was determined by plasma iohexol
disappearance curves (iGFR) and using the bedside
CKiD study creatinine-based equation (eGFR) (15,21);
details of GFR measurement have been previously published (22). Plasma vitamin D and ﬁbroblast growth factor 23 (FGF23) were measured as previously described
(23,24). Blood and urine specimens were analyzed at the
study’s central biochemistry laboratory (University of
Rochester, Rochester, NY).
Echocardiography
Echocardiography measurements were obtained every
other year, starting 1 year after study entry. M-mode and
Doppler echocardiography were performed at each
center; analyses of echocardiographic data were performed by the Cardiovascular Core Imaging Research
Laboratory at Cincinnati Children’s Hospital Medical
Center. For achievement of standardization of echocardiographic images across centers, qualifying recordings were sent to each center and certiﬁed at the core
laboratory.
LVM was measured by two-dimensional directed
M-mode echocardiography at rest according to the American Society of Echocardiography criteria (25). This method
applies measurements of LV end-diastolic cavity (LVED),
interventricular septal thickness, and posterior wall thickness
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and accurately predicts LVM through the following
equation:

LVM5 0:8 1:04 ðLVED 1 posterior wall thickness
1 interventricular septal thicknessÞ3 2 LVED3



1 0:6:

LVM index (g/m2.7) was calculated by dividing LVM by
height in meters to the power of 2.7 (12).
Statistical Analyses
The ﬁrst component of the analyses described CVD risk
factors by sex at visit 2 when the ﬁrst echocardiography
data were collected. The second component described
differences in LVM by sex, adjusting for different metrics
of body size, including age, weight, height, and eLBM,
using bivariate and multivariate regression models. Subjects who had repeat echocardiograms could contribute
multiple LVM measurements, with corresponding age,
weight, height, and eLBM updated for that visit.
Characterizing CVD and CKD Risk Proﬁles by
Sex. Univariate descriptive statistics were used to characterize
CVD and CKD risk proﬁles. Wilcoxon rank sum and Fisher
exact tests compared continuous and categorical variables. We
calculated the prevalence of LVH among girls and boys as
deﬁned by Khoury et al. as left ventricular mass index (LVMI) =
(LVM/height2.7) .95th percentile for sex and age (26). We performed repeated linear regression models of LVMI (in the log
scale) and logistic regression models of LVH, with the primary
independent variable being sex. These models used generalized
estimating equations to account for repeated observations
within individuals. The base model included the same covariates as those reported by Kupferman et al. (5), including age,
race, visit, systolic BP z-score, height, eGFR, anemia, antihypertensive medications, CKD duration, percent life with CKD, and
glomerular diagnosis. To investigate additional variables that
may explain sex differences, we included Tanner stage, cholesterol, vitamin D levels, and FGF23 levels in separate models
and compared the adjusted effect of sex to the base model.
We also calculated the prevalence of LVH using recently
published reference centiles expressing LVM relative to eLBM,
with LVH deﬁned as LVMI-for-eLBM .95th percentile (27),
and compared with LVH estimates based on the Khoury
equation (26). eLBM was calculated for each subject visit according to sex-speciﬁc equations described by Foster et al. (13):
Boys: lnðLBMÞ 5 22:9585 1 0:8208∗ lnðheightÞ 1 0:5607∗ lnðweightÞ 1
0:0000184∗ weight2 2 0:0159∗ BMIz2 1 0:0135∗ age 1 0:0225∗ Black;
Girls: lnðLBMÞ5 23:9361 1 0:9786∗ lnðheightÞ 1 0:6431∗ lnðweightÞ 2
0:0118∗ BMIz2 1 0:029∗ Black:

Association of LVM with Different Metrics of Body
Size, by Sex. We analyzed LVM in relation to different
metrics of body size including age (years), weight (kg), height
(cm), and eLBM (kg), using echocardiographic data from all
available visits. Four bivariate models were of the form:
logðLVM in gramsÞ5a0 1 a1 ðGirlsÞ 1 d0 Z 1 d1 Z 3 Girls 1 e;
where Z represents included covariates: age centered at 14
years, weight in the log scale centered at 46 kg, height in the
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log scale centered at 150 cm [as well as the quadratic of log
(height)], and eLBM in the log scale centered at 30 kg. These
values were chosen as the mean levels for the population,
and centering provides an interpretable intercept. Z3Girls
represents covariate interactions with sex to evaluate sex
differences in the effect of covariates on LVM. Generalized
estimating equations assuming an independent correlation
structure were used to account for repeated measurements
within individuals. The differences by sex were determined
by the statistical signiﬁcance of the parameters a1 and d1.

Results
Cardiovascular, Metabolic, and Kidney Disease Risk
Factors, by Sex
The analysis included 681 children (411 boys and 270
girls). Table 1 presents demographic characteristics by sex
at ﬁrst visit with an echocardiography study. The age
range for the total cohort was 2.0–19.2 years and was similar by sex. Boys and girls had similar distributions of
black race; girls were more likely to be of Hispanic ethnicity. Girls tended to have more advanced Tanner stage,
consistent with earlier pubertal development among normal girls compared with boys (28). CKD severity, as measured by GFR and proteinuria, did not differ by sex.
Compared with boys, girls had a lower height-for-age zscore and a lower eLBM. There was no difference in the
prevalence of obesity by sex.
Table 2 describes CVD risk factors by sex. Girls were less
likely to have uncontrolled hypertension (26% versus 38%,
P=0.001), had lower diastolic BP z-scores (+0.3 versus +0.6,
P=0.001), and had lower prevalence of high triglycerides
(38% versus 47%, P=0.03) compared with boys. Girls were

more likely to receive antihypertensive therapy and
angiotensin-converting enzyme inhibitors. There was no
sex difference in prevalence of ambulatory hypertension.
Girls had lower vitamin D-1,25 levels compared with boys
(30.4 versus 33.6, P=0.01), although there was a similar
distribution of vitamin D-25 and FGF23 levels between
sexes. Girls also had slightly lower median hemoglobin
compared with boys (12.4 versus 12.8 g/dl, P=0.01). We
performed a subgroup analysis restricted to postpubertal
boys and girls (i.e., Tanner stage 4 or 5). This analysis
showed similar results, indicating that girls did not
have a higher prevalence of CVD risk factors. A similar
pattern of lower median hemoglobin levels and lower vitamin D-1,25 levels, with similar vitamin D-25 and FGF23
levels among postpubertal girls compared with boys was
observed.
Association of LVM with Different Metrics of Body Size, by
Sex
Median LVMI was similar between sexes at all visits
(Table 2). Using the deﬁnition of LVH described by
Khoury et al. (26), the prevalence of LVH was higher
among girls compared with boys at visit 2 (16% versus
9%, P=0.01). However, when deﬁning LVH using LVM
relative to eLBM centile curves (27), there was no
longer a difference in the prevalence of LVH between girls
and boys (18% versus 17%, P=0.92).
Table 3 shows the results of the multivariable linear regression model of LVMI and logistic regression model of
LVH with the primary independent variable of sex, adjusted for CVD risk factors (including 145 cases of LVH
out of 1398 person visits). These models indicate no

Table 1. Baseline demographic features comparing boys and girls

Variable
Age, yr
Black race
Hispanic ethnicity
Tanner stage
1
2
3
4
5
Glomerular diagnosis
CKD duration, yr
iGFR, ml/min per 1.73 m2
eGFR, ml/min per 1.73 m2
Urine protein-to-creatinine, mg/mg
Height, cm
Height z-score
Weight, kg
Weight z-score
Body mass index, kg/m2
BMI z-score
Obese
Lean body mass, kg

Boys (n=411)

Girls (n=270)

11.0 [7.4, 14.4]
22 (92)
12 (49)

11.3 [7.8, 14.8]
19 (52)
18 (49)

62 (242)
8 (33)
8 (32)
15 (59)
7 (27)
23 (94)
8.5 [4.4, 13.1]
53.6 [38.2, 72.4]
52.6 [37.9, 66.9]
0.33 [0.11, 1.06]
140.8 [118.0, 163.3]
20.47 [21.26, 0.28]
37.9 [22.6, 56.1]
0.09 [20.77, 0.89]
18.5 [16.3, 21.8]
0.47 [20.31, 1.29]
17 (67)
27.4 [17.3, 42.5]

51 (129)
9 (23)
11 (28)
15 (39)
14 (36)
33 (90)
7.4 [3.3, 11.5]
49.6 [38.9, 68.0]
53.2 [41.0, 67.7]
0.39 [0.13, 0.94]
139.4 [120.5, 157.5]
20.66 [21.59, 0.15]
37.6 [24.4, 54.2]
20.10 [21.03, 0.98]
18.7 [16.3, 23.3]
0.43 [20.31, 1.38]
17 (45)
25.9 [17.1, 36.0]

P Value
0.29
0.34
0.03
0.01

0.004
0.04
0.18
0.41
0.33
0.24
0.05
0.98
0.31
0.37
0.95
0.92
0.03

Continuous variables expressed as median [interquartile range]. Categorical variables expressed as percentage (number of subjects).
eGFR calculated using bedside CKiD equation. iGFR, iohexol GFR; BMI, body mass index.
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Table 2. Cardiovascular disease risk factors comparing boys and girls

Variable

Boys (n=411)

Girls (n=270)

P Value

Systolic BP z-score
Diastolic BP z-score
Uncontrolled hypertension
Elevated ambulatory systolic BP
Elevated ambulatory diastolic BP
Ambulatory hypertension
Antihypertensive therapy
Angiotensin-converting enzyme inhibitor therapy
Angiotensin receptor blocker therapy
Calcium channel blocker
.1 antihypertensive medication
High phosphorous
Hemoglobin, g/dl
Total cholesterol, mg/dl
High total cholesterol
HDL cholesterol, mg/dl
Low HDL cholesterol
LDL cholesterol, mg/dl
High LDL cholesterol
Triglycerides, mg/dl
High triglycerides
Vitamin D-1,25 DOH
Vitamin D-25 OH
Plasma FGF23, RU/ml
Number of echocardiographic studies
1 study
2 studies
$3 studies
LVMI at visit 2, g/m2.7
LVMI at visit 4, g/m2.7
LVMI at visit 6, g/m2.7

0.39 [20.3, 1.03]
0.59 [20.05, 1.16]
38 (155)
45 (121)
42 (113)
54 (146)
59 (243)
44 (182)
9 (38)
13 (54)
14 (59)
9 (39)
12.8 [11.8, 13.8]
169 [147, 191]
25 (98)
49 [40, 58]
12 (47)
96 [74, 114]
12 (47)
101 [70, 150]
47 (187)
33.6 [25.4, 42.4]
28.3 [21.1, 35.5]
127.4 [81.2, 217.9]

0.17 [20.62, 0.92]
0.30 [20.26, 1.0]
26 (69)
39 (72)
40 (73)
48 (88)
69 (185)
57 (154)
10 (27)
13 (35)
18 (48)
7 (18)
12.4 [11.6, 13.4]
173 [150, 197]
21 (57)
50 [42, 59]
9 (25)
98 [81, 117]
11 (30)
98 [73, 141]
38 (101)
30.4 [23.5, 38.6]
28.3 [19.7, 35.7]
144.4 [91.4, 186.8]

0.05
0.001
0.001
0.25
0.70
0.21
0.02
0.001
0.79
1.00
0.24
0.21
0.01
0.25
0.35
0.23
0.37
0.14
0.90
0.96
0.03
0.01
0.73
0.38
0.44

52 (213)
26 (105)
23 (93)
31.6 [26.1, 37.8]
31.2 [26.7, 36.2]
26.1 [21.5, 32.5]

47 (127)
27 (73)
26 (70)
29.9 [25.0, 37.1]
30.3 [24.2, 35.1]
26.9 [22.3, 32.5]

0.23
0.05
0.60

Continuous variables expressed as median [interquartile range]. Categorical variables expressed as percentage (number of subjects).
Vitamin D-1,25 DOH, 1,25-dihydroxyvitamin D; Vitamin D-25 OH, 25-hydroxyvitamin D; FGF23, ﬁbroblast growth factor 23; LVMI,
left ventricular mass index.

differences in LVMI between boys and girls in the base
linear model, and increased odds of LVH among girls in
the base logistic model. The increased odds of LVH among

girls persisted after adjustment for CVD risk factors. Of
note, the current CKiD study dataset used in this analysis
includes more echocardiography studies since the

Table 3. Multivariable regression models of LVMI and LVH

Model
Base model
Base model+Tanner stage
Base model+high triglycerides
Base model+FGF23
Base model+Vitamin D-1,25 DOH
Base model+Vitamin D-25 OH
Based model+Tanner stage+high triglycerides+
FGF23+Vitamin D-1,25 DOH+Vitamin D-25 OH

LVMI (in the Log Scale)
Girls versus
Boys, % (95% CI)

Odds of LVH among
Girls versus
Boys (95% CI)

23.6 (27.3 to +0.2)
24.9 (28.5 to 21.1)
23.5 (29.2 to +0.5)
21.9 (26.7 to +3.1)
24.1 (28.2 to +0.3)
24.1 (28.3 to +0.3)
23.6 (29.1 to +2.2)

2.30 (1.44 to 3.67)
2.25 (1.40 to 3.63)
2.17 (1.33 to 3.52)
3.08 (1.74 to 5.44)
1.97 (1.12 to 3.48)
1.99 (1.12 to 3.51)
2.11 (1.04 to 4.31)

Base models all adjusted for visit, systolic BP z-score (by visit), height (by visit), eGFR, race (black versus other), anemia, angiotensinconverting enzyme inhibitor/angiotensin receptor blocker use, other antihypertensive medications, age, CKD duration, percent life
with CKD, and glomerular diagnosis. LVMI, left ventricular mass index; LVH, left ventricular hypertrophy; 95% CI, 95% conﬁdence
interval; FGF23, ﬁbroblast growth factor 23; Vitamin D-1,25 DOH, 1,25-dihydroxyvitamin D; Vitamin D-25 OH, 25-hydroxyvitamin D.
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previous report (5), explaining differences with the previous results but consistent inferences.
Figure 1 provides the bivariate associations of different
metrics of body size. The dashed lines represent nonparametric splines (black for girls, gray for boys), and the solid
lines are based on the bivariate linear regressions: the consistency of the two indicate good ﬁt between the model
and the data. When adjusting for age, girls had a signiﬁcantly lower LVM at age 14 [214.7%; 95% conﬁdence interval (95% CI), 218.5% to 210.6%], and the effect of age
on LVM differed by sex: LVM in boys increased by 9.2%
per year while LVM in girls increased by 7.1% per year
(P for difference ,0.01). Similarly, for weight, girls had an
8% lower LVM at the median weight of 46 kg (28.1%; 95%
CI, 211.2% to 24.7%), and the effect of weight on LVM
was borderline signiﬁcant (P=0.05). At the median height
of 150 cm, girls were 4.3% lower than boys, and this was
also borderline signiﬁcant (95% CI, 28.3% to +0.02%;
P=0.05), although the slopes of height were nonsigniﬁcant
for the linear term (P=0.36) and the quadratic term
(P=0.12). Lastly, there were no differences in LVM between girls and boys at the median eLBM of 30 kg (girls
were 0.7% higher; 95% CI, 22.6% to +4.2%) and for the
change associated with eLBM (P=0.77). In multivariate
analyses, incorporating the predictors from the previous
four regressions, there were no differences by sex. Furthermore, eLBM was the strongest predictor of LVM.

Discussion
Based on a prior report from the CKiD study showing a
four-fold higher odds of LVH among girls compared with
boys (5), we further explored sex differences in CVD risk factors and LVH in children with CKD. Estimates of LVH based
on traditional height indexing showed a persistently higher
proportion of LVH among girls, despite a lack of increased
prevalence of CVD risk factors. When deﬁning LVH using
LVM relative to eLBM centile curves, there was no longer a
difference in LVH prevalence by sex. In a regression model
adjusting for eLBM, there were no sex differences in LVM.
If one accepts the current height-based indexing of LVM
to deﬁne LVH in children, our study did show a higher
prevalence of LVH among girls with CKD. One potential
explanation for the excess burden of LVH among girls is a
sex-speciﬁc end-organ response to hypertension. In a study
of young adults with hypertension, women were more
likely to develop LVH compared with men, adjusted for
ambulatory BP and other CVD risk factors (9). In adults
with metabolic syndrome, hypertension was associated
with LVH in both men and women, but waist circumference, hyperinsulinemia, and hyperglycemia were independently associated with LVH only in women, suggesting
possible sex differences in the pathogenesis of LVH (10).
Sex differences in cardiac response to hypertension among
children with CKD will need to be explored further in
future studies.

Figure 1. | Associations between left ventricular mass (LVM; in grams) and different metrics of body size show no difference in LVM by sex
when adjusted for estimated lean body mass. Metrics include age, weight, height, and estimated lean body mass among 411 boys contributing
815 echocardiography studies and 270 girls contributing 515 echocardiography studies.
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Another potential explanation for the higher proportion of LVH among girls is that there are other CVD risk
factors that may disproportionately affect girls. We did
ﬁnd that girls had slightly lower vitamin D-1,25 levels
than boys. Vitamin D deﬁciency has been associated with
CVD and mortality in the CKD population (29–31).
However, the signiﬁcance of slightly lower vitamin D1,25 levels among girls in the context of similar vitamin
D-25 and FGF23 levels is unclear. We also found that
girls had slightly lower hemoglobin levels compared
with boys, but the difference was small and likely not
of clinical signiﬁcance. Finally, there may be other, currently unmeasured variables that may account for the
higher proportion of LVH among girls with CKD. For
example, both boys and girls with CKD are known to
have hormonal variations with pubertal development
(32); future studies are needed to determine if these
hormonal abnormalities may explain a sex-speciﬁc risk
for LVH.
Alternatively, the excess proportion of LVH among
girls without a corresponding higher prevalence of
known CVD risk factors may indicate that the current
deﬁnition of LVH may not accurately categorize cardiac
hypertrophy in this population. There is no consensus on
how best to deﬁne LVH in children. LVM is known to be
strongly associated with sex, height, body surface area,
and LBM (33,34). It is important that LVM be scaled to
the most appropriate measure of body size to allow
meaningful comparisons across a range of body sizes.
LVM scales best to LBM in the normal population
(12,34–37). Since it is not always clinically feasible to
measure LBM, height has often been used as a surrogate for LBM, and LVM has traditionally been
indexed to height 2.7 (38,39). In adults, an absolute
LVMI.51 g/m2.7 has been associated with higher cardiovascular morbidity and mortality (39). However, the
relationship between LVM and height differs across ages
(11,26,40), and a single cut-off point for LVM/height2.7
has been shown to be inappropriate for deﬁning LVH
across pediatric age groups (40). To address this, Khoury
et al. developed quantile curves for LVM/height2.7, and
LVH has traditionally been deﬁned as LVMI .95th
percentile for sex and age (26).
Prior CKiD study publications have used these 95th
percentile curves to deﬁne LVH. However, this deﬁnition
of LVH may be limited by the relatively small sample size
of 2273 boys and girls to represent the normal population
aged 0–18 years. Additionally, the assumption that there
is a constant difference in LVMI by sex across all ages at
the 95th percentile (i.e., LVH threshold for boys is about
2.7 g/m2.7 higher than girls, regardless of age) may not be
the case. Previous studies in children with CKD have
shown that indexing LVM to different measures of body
size leads to different estimates of LVH prevalence (11).
Additionally, LVM indexed to height leads to underestimation of relative LVM in thin individuals and overestimation of LVM in overweight individuals (34). Since
individuals in the CKiD study are, on the whole, relatively
overweight, this may have led to an overestimation of
LVH prevalence.
Since LVM is expected to depend primarily on LBM, our
analysis showed that an estimating equation for LBM
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explained differences in LVM between boys and girls, and
this relationship was not different by sex. Indeed, Figure 1
shows that, while height was a strong predictor of LVM,
eLBM more fully explained sex differences in LVM, as evidenced by complete overlap of the nonparametric splines
and model lines between boys and girls. Foster et al. also
recently reexamined the data used to generate the LVMI
for age curves presented by Khoury et al. to deﬁne new
LVM reference centiles expressing LVM relative to LBM
(27). This study yielded an overall lower estimate of the
prevalence of LVH. In fact, when these new centile curves
were applied to the current CKiD study population, a substantial number of subjects were reclassiﬁed compared
with the Khoury method, and girls and boys had a similar
percentage of LVH. Since a simple equation using age,
height, weight, and BMI z-scores has been developed, further analysis of LVM indexed to LBM in other samples of
typically developing youth and in the CKD population
would further our understanding of appropriate cut-offs
to deﬁne LVH.
Limitations of this study include not having data on all
potential CVD risk factors that may explain sex differences
in LVH. In addition, we used cut-offs for LVH which were
developed in cohorts of healthy children and have not been
validated in the CKD population, although these cut-offs
are typically used clinically for children with CKD. Finally,
we deﬁned LVH based on echocardiographic criteria.
Future studies using cardiac magnetic resonance imaging may provide more accurate measures of cardiac
hypertrophy.
In conclusion, this study shows similar CVD risk proﬁles
in girls and boys with CKD, and highlights the current
limitations in deﬁning LVH in children with CKD. As
clinicians frequently use LVH as a marker of end-organ
damage, an accurate deﬁnition is essential in order to
classify CVD risk and prevent future morbidity and
mortality. Indexing LVM to eLBM may be an alternative
to height indexing, and further research in a normal
population should investigate this relationship more
closely.
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